Under the multiyear, multiprogram agreement, Frontier's chemoproteomics platform, which identifies small molecules for programs directed to novel E3 ligases and certain oncology and immunology targets, will be used.

AbbVie will pay Frontier an upfront cash payment of $55 million, and Frontier will be eligible to receive additional milestone payments up to $100 million within the first 12 months of the collaboration. AbbVie also will reimburse Frontier's research and development costs through specific stages of preclinical development.

AbbVie, I-Mab partner on cancer mAb, I-Mab raises $418M
AbbVie and I-Mab have signed a global collaboration agreement for the development and commercialization of lemzoparlimab (TJC4), an anti-CD47 monoclonal...

AbbVie, Harvard partner on $30M emerging virus research
AbbVie and Harvard University announced a $30 million collaborative research alliance to study therapies against emerging viral infections.

Alpine and AbbVie to develop, commercialize immunotherapy
Alpine Immune Sciences and AbbVie have entered an exclusive worldwide option and license agreement for ALPN-101, a dual cluster of differentiation 28...

AbbVie licenses antibody technology for COVID-19
AbbVie, Harbour BioMed, Utrecht University, and Erasmus Medical Center announced that they have entered into a collaboration to develop a novel antibody...